Matching articles for "bexagliflozin"
Issue 1742 · November 24, 2025
Noninsulin Drugs for Type 2 Diabetes

Diet, exercise, and weight loss can improve glycemic control, but most patients with type 2 diabetes eventually require glucose-lowering pharmacotherapy. An A1C goal of <7% (while minimizing hypoglycemia) is…

Med Lett Drugs Ther. 2025 Nov 24; 67(1742):185-92 doi:10.58347/tml.2025.1742a
Diet, exercise, and weight loss can improve glycemic control, but most patients with type 2 diabetes eventually require glucose-lowering pharmacotherapy. An A1C goal of <7% (while minimizing hypoglycemia) is recommended for most patients to prevent or reduce the microvascular complications of diabetes (retinopathy, nephropathy, neuropathy). An A1C target of <8% may be appropriate for patients who are older, have comorbid conditions, or are at risk of serious hypoglycemia-associated adverse events.
Issue 1742 · November 24, 2025 Free
Comparison Chart: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors (online only)

View the Comparison Chart: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors

Med Lett Drugs Ther. 2025 Nov 24; 67(1742):e191-4 doi:10.58347/tml.2025.1742b
View the Comparison Chart: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors
Issue 1723 · March 3, 2025
A Renal Indication for Semaglutide (Ozempic)

The injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide ( Ozempic – Novo Nordisk) has been approved by the FDA to reduce the risk of sustained eGFR decline, end-stage kidney disease, and…

Med Lett Drugs Ther. 2025 Mar 3; 67(1723):38-40 doi:10.58347/tml.2025.1723d
The injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide ( Ozempic – Novo Nordisk) has been approved by the FDA to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease (CKD). It is the first GLP-1 receptor agonist to be approved in the US for this indication.
Issue 1689 · November 13, 2023 Free
In Brief: Empagliflozin (Jardiance) for Chronic Kidney Disease

The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin ( Jardiance – Boehringer Ingelheim/Lilly) is now FDA-approved to reduce the risk of sustained eGFR decline, end-stage kidney disease,…

Med Lett Drugs Ther. 2023 Nov 13; 65(1689):183-4 doi:10.58347/tml.2023.1689c
The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin ( Jardiance – Boehringer Ingelheim/Lilly) is now FDA-approved to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease (CKD) at risk of progression. It is also approved to improve glycemic control in patients ≥10 years old with type 2 diabetes, to reduce the risk of cardiovascular death and hospitalization for heart failure (HF) in adults with HF, and to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.
Issue 1683 · August 21, 2023
Bexagliflozin (Brenzavvy) — A Fifth SGLT2 Inhibitor for Type 2 Diabetes

Bexagliflozin ( Brenzavvy – TheracosBio), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved by the FDA to improve glycemic control in adults with type 2 diabetes. It is the fifth SGLT2…

Med Lett Drugs Ther. 2023 Aug 21; 65(1683):130-2 doi:10.58347/tml.2023.1683b
Bexagliflozin ( Brenzavvy – TheracosBio), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved by the FDA to improve glycemic control in adults with type 2 diabetes. It is the fifth SGLT2 inhibitor to be approved in the US for this indication (see Table 4).